Breast Cancer (MSI Mutation): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 55-year-old postmenopausal Caucasian female patient presented with a palpable right breast mass in 2011. A diagnostic mammogram and ultrasound revealed a 4 cm mass and suspicious axillary lymphadenopathy. She received neoadjuvant chemotherapy and underwent breast conservation surgery. In January 2015, the patient returned for a follow-up visit complaining of a dry cough for the past two months. A CT chest scan identified multiple lung nodules. In July 2016, after complaints of headaches, an MRI identified three lesions in the right frontal, right cerebellar, and left frontal lesion.

Originally posted on a forum in the ASCO Connection, participants now have the opportunity to claim CME, MOC, completion, or participation certificates for completing this activity.

Learning Objectives

  • Evaluate the indications of genetic testing and use of different panels in patients with triple negative breast cancer
  • Examine the evolving targeted therapies for patients with advanced/recurrent triple negative breast cancers
  • Analyze potential biomarkers for predicting response to immunotherapy in breast cancer patients

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™ 
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.
Important Notes
  • This course expires on April 26, 2020. Participants must complete all necessary course components by this date to receive credit.